Low GSK-3β immunoreactivity in postmortem frontal cortex of schizophrenic patients

Nitsan Kozlovsky, R. H. Belmaker, Galila Agam

Research output: Contribution to journalArticlepeer-review

163 Scopus citations


Objective: Glycogen synthase kinase-3 (GSK-3) is a protein kinase that is highly abundant in the brain. It is involved in signal transduction cascades of multiple cellular processes, particularly neurodevelopment. In an attempt to explore possible involvement of GSK-3β in psychiatric disorders, the authors examined its levels in postmortem brain tissue. Method: Western blot analysis was performed to measure GSK-3β in the frontal cortex of 14 schizophrenic patients, 15 patients with bipolar disorder, 15 patients with unipolar depression, and 14 normal comparison subjects. Results: GSK-3β levels were 41% lower in the schizophrenic patients than in the comparison subjects. Other diagnostic groups did not differ from the comparison subjects. Conclusions: These results are consistent with the notion that schizophrenia involves neurodevelopmental pathology. It remains to be investigated whether the active fraction of GSK-3β, or its activity, is also low in frontal cortex of schizophrenic patients and if this is also reflected in other brain regions.

Original languageEnglish
Pages (from-to)831-833
Number of pages3
JournalAmerican Journal of Psychiatry
Issue number5
StatePublished - 1 May 2000

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Low GSK-3β immunoreactivity in postmortem frontal cortex of schizophrenic patients'. Together they form a unique fingerprint.

Cite this